Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $7.77 Million - $29.8 Million
-600,010 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$25.57 - $44.88 $6.85 Million - $12 Million
-267,714 Reduced 30.85%
600,010 $26.9 Million
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $1.36 Million - $1.84 Million
73,355 Added 9.23%
867,724 $17.5 Million
Q3 2020

Nov 16, 2020

SELL
$15.19 - $22.4 $452,662 - $667,520
-29,800 Reduced 3.62%
794,369 $15.5 Million
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $781,611 - $2.38 Million
126,270 Added 18.09%
824,169 $14.6 Million
Q1 2020

May 15, 2020

BUY
$5.4 - $9.22 $1.18 Million - $2.02 Million
218,825 Added 45.68%
697,899 $4.93 Million
Q3 2019

Nov 14, 2019

BUY
$9.41 - $16.56 $4.28 Million - $7.54 Million
455,173 Added 1904.41%
479,074 $5.75 Million
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $214,630 - $309,756
23,901 New
23,901 $289,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.99B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Novo Holdings Portfolio

Follow Novo Holdings and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.